Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
Founder/CEO buying through controlled entity Bluerock Asset Management; 3-day purchase campaign Sept 28–30 at $12.44–$12.61 avg; non-traded public REIT; stock flat since buy at $12.62.
Purchased indirectly through Ault & Company at $0.50/share vs current market $0.1644 — premium strongly indicates private placement, not open-market purchase. Micro-cap; discount this signal.
Australian cardiac medtech (DurAVR transcatheter aortic valve); L1 Capital accumulating on weakness; avg buy ~$7.68 across Sept 30–Oct 1; stock now $7.61 (−0.9%).
Cluster buy with CFO same day (Sept 30) after clinical trial pause drove stock lower; avg $37.38; now $38.93 (+4.1%). Stock up 5.2% on the day of disclosure.
New position; CFO buys alongside CEO on same day (Sept 30) after clinical trial pause selloff; avg $37.32; now $38.93 (+4.3%). First reported direct holding.
New director establishing initial stake; open-market purchase Oct 1 at $24.33; now $24.11 (−0.9%). First reported holding.
AIThe day in insider buying
SEC Form 4 Insider Scan — October 2, 2026
Scanned the last 24 hours of EDGAR Form 4 filings (filed Oct 1–2, 2026). 7 qualifying buys (≥ $250K, transaction type P) totalling ~$23.8M.
Headline Filings
GPI — Conifer Management LLC (10% Owner) bought 34,593 shares ≈ $8.4M at $243.35 avg; now $256.70 (+5.5% since buy). Activist fund continues aggressive accumulation — 27 separate transactions Sept 28–30 — after securing a board seat Sep 21. (filing)
BPRE — Ramin Kamfar (Director/Founder) bought 425,590 shares ≈ $5.4M at $12.55 avg via Bluerock Asset Management; now $12.62 (+0.6% since buy). Non-traded public REIT; 3-day buying campaign Sept 28–30. (filing)
GPUS — Milton C. Ault III (Executive Chairman via Ault & Company) bought 10,000,000 shares ≈ $5.0M at $0.50; now $0.1644 (−67.1% from filing price). ⚠️ Price far above current market — strongly indicates private placement, not open-market purchase. (filing)
AVR — L1 Capital Pty Ltd (10%+ Owner) bought 397,226 shares ≈ $3.1M at $7.68 avg across Sept 30–Oct 1; now $7.61 (−0.9% since buy). Australian cardiac medtech (transcatheter aortic valve replacement); L1 adding on weakness. (filing)
XENE — Ian Mortimer (President & CEO) bought 30,000 shares ≈ $1.1M at $37.38; now $38.93 (+4.1% since buy). Cluster signal: CEO and CFO both bought same day after clinical-trial-pause selloff. (filing)
XENE — Thomas Kelly (CFO) bought 15,000 shares ≈ $560K at $37.32; now $38.93 (+4.3% since buy). New position established in tandem with CEO purchase. (filing)
GME — Turner Nat (Director) bought 10,462 shares ≈ $255K at $24.33; now $24.11 (−0.9% since buy). New director establishing initial stake. (filing)
Notes
Top theme: Activist accumulation in autos (GPI/Conifer keeps buying through weakness, now +5.5%) and healthcare (XENE CEO+CFO cluster buy after trial pause — strongest conviction signal of the day; stock already recovering).
GPUS flag: The Ault & Company purchase of 10M GPUS shares at $0.50 codes as "P" but current market is $0.1644 — nearly a 3× premium to market. This is characteristic of a private placement, not an open-market buy, and should be discounted as a bullish signal.
10% owners dominant: Four of seven qualifying buys are from institutional 10%+ owners (Conifer/GPI, L1 Capital/AVR, Bluerock AM/BPRE, Ault & Company/GPUS). Management buys at XENE (CEO + CFO) are the cleanest, most conviction-rich signals in today's scan.
Most-bought stocks, last 30 days
RSG$279M · 2 buys, 2 insidersRepublic Services, Inc.
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's
stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what
average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free,
and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.